Hutchmed (china) Share Discussion Threads

[pfm99] 06/12/2021 16:29

Current price, volatility and backdrop does not look good for the odds that General Atlantic will exercise their warrant to subscribe for another $100m of stock at $30 granted in June 2020, this expires on Jan 03 2022.

[steeplejack] 06/12/2021 15:53

Fun and games.Reading the Wall Street journal this weekend relates how some US fund managers now believe that a good number of Chinese companies will delist from the US market.Maybe these ideas have been hardened by DiDi but its become something of a ‘default’; view on the Street.You have to wonder whether HMEDs decision to belatedly list on the HK exchange wasn’t in part prompted by listing concerns in the US,it wouldn’t do to only have an AIM listing in the UK.The Chinese authorities are encouraging companies to seek equity fundings in home markets plus US authorities are making life difficult for chinese companies in respect of disclosure.HMED is so volatile that its difficult to discern a pattern but this political backcloth is clearly not helpful.The markets are explicably feral just now and of course we’re approaching the US tax year end which all adds to shuffle and sector rotation

[nerdofsteel] 06/12/2021 14:52

massive clinical progress and a massive drop in the share price but it's nothing to do withHutchmed itself, Beigene and all major china biotechs have been hammered in the past few days

[bulltradept] 06/12/2021 14:15

Looking to go in under £4.60!

[fionascott1234] 06/12/2021 14:11

Volatility !

[nerdofsteel] 03/12/2021 07:58

SULANDA® (surufatinib) has been included in the NRDL and ELUNATE® (fruquintinib) will continue to be on the list but ORPATHYS® (savolitinib) is not. Progress anyway because the biggest opportunity for the two is Sulanda.

[steeplejack] 29/11/2021 18:41

At long last i comprehend the enigma of Hutchy's share price moves.When the market goes up,HMED goes down and visa versa,anything else is pretty much a sideshow.

[fionascott1234] 29/11/2021 17:05

3.4% up then 3.4% down.The volatility you were talking about......

[1jat] 29/11/2021 09:08

HK volumes have been strong since the beginning of last week…..it is HK that is driving the current rally….although the US has joined in to some extent.

[its the oxman] 29/11/2021 08:28

Was a bit bemused by the extent of the sustained fall. Now a sustained rally. Who knows where this is going.

[fionascott1234] 23/11/2021 17:47

That's better, down 4.4%. You get dizzy when it fluffs up 40-odd p for no fathomable reason.

[whatja] 23/11/2021 14:29

Steeplejack….strap yourself in and expect quite a bit of volatility.

I expect a run up in anticipation of the fda approving surufatinib but there will be a pullback if that gets overdone and then the result may move the share price significantly up or down with the risk of a heavy fall on the downside if it is not approved. Traders will not want to be exposed to that event hence I think there will be a pull back or hold in the run up to the decision, but will pile in on the news.

[steeplejack] 22/11/2021 10:29

The biotech sector has been weak of late.The gene sequencing stocks in the US,for example,have taken a good thumping.With dear old Hutchy,trying to rationalise the stock price moves might prove a fruitless exercise.A lot of the smaller biotechs enjoy a premium resulting from speculation that they might get 'gobbled up'by a major as the pipeline develops.Hutchmed clearly doesn't benefit from takeover speculation with Hutchinson retaining its sizeable holding.Despite my annoyance at the fairly dismal share performance,i find myself concluding that this remains a very sound investment.I'm also pretty sure that we can expect to sprint back to £6 in short order leaving me with the quandary of whether to sell in anticipation of another sharp fall back!

[whatja] 22/11/2021 09:55

DBAVFN
The market has a current price that is based on a lot of assumptions about efficacy, alternative treatments market share pricing time to market.
Given the uncertainty, it is not surprising that the market heavily discounts the future of the company.
Those invested here are clearly betting that when 2025 comes around the uncertainty is much reduced and the value of the assets is much clearer (and hopefully higher….but we cannot assume all the assets will be commercially successful)….
What we know is that the company is currently well capitalised and is making headway with its pipeline….it is not likely to run out of cash as many development pharma cos can.
Today’s market movement of 10% shows the short term perils of being out of the company.
It will be interesting to see if there is an RNS about an increase ina shareholding or hear of any news that emerges about why the jump happened….it looks like a decent sized buy program was executed early in HK.

[whatja] 22/11/2021 08:07

11% gain in HK on the back of 3.5m shares traded.
New buyer?

[dbadvn] 19/11/2021 17:45

I remember when it was 45p !!

Its the financials going forward that matter now. Market has acceptyed and priced the clinical success.

[nerdofsteel] 19/11/2021 17:16

3 years ago it was £5.84 so all the huge financial and clinical progress has clearly meant nothing to the market

[fionascott1234] 18/11/2021 15:17

I remember when this was £6.56 !!!

[steeplejack] 18/11/2021 14:58

Perhaps the Deutsche Bank presentation fell a bit flat.Hard to find a buyer in the US today or perhaps Alibaba's poor figures simply added to a desire to avoid all things Chinese.This stock really needs a good kick up the rear.

[nerdofsteel] 17/11/2021 09:19

DB Investor conference today @ 13:00

[fionascott1234] 10/11/2021 15:00

Heading for another down day.

[nerdofsteel] 09/11/2021 08:46

5 years ago I was making a decision as to whether to double my already considerable investment in HCM or open a position with BGNE. I chose the former, unfortunately......

Beigene came from nowhere but have been far bolder and dynamic in their multi-pronged strategy, partnering and in-licensing with Celgene whilst at the same time creating their own innovation.

It does beg the question as to why Hutchmed didn't do a similar thing, market some other players drugs in China, leveraging its already large commercial organisation, whilst creating its own innovation in parallel and continuing with its OTC business.

I am not sure at the moment what to think. Our CEO says the Company will be a very large player by 2025 with 9 drugs launched in China and 5 outside of China. I hope this will transpose into a valuation much larger than today's but nothing the Company does seems to make much of a difference any more.

The Asian listing, the north-south stock connect program, inclusion in various Asian indices, incredible pipeline progresss but the same valaution malaise.

[lauders] 09/11/2021 02:23

At the time of typing this HCM is down (-0.53%) in HK yet again. It was up in the States slightly (+ 0.27%) yesterday. Seems that 13 is turning out to be "not such a lucky number" in keeping with the West's reading of the numeral! Come on HCM give us some real news of substance to kick us back in the right direction!